Breast Cancer Treatments

Find Breast Cancer Treatments

Generic Name

Trastuzumab

Brand Names

Ontruzant, Ogivri, Trazimera, Kanjinti, Herceptin, Herceptin Hylecta, Herzuma

FDA approval date: February 10, 2017

Classification: HER2/neu Receptor Antagonist

Form: Injection, Kit

What is Ontruzant (Trastuzumab)?

TRAZIMERA is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug, Biological

Study Phase: Phase 3

Summary: Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) mean...

A Phase III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Who is this study for: Patients with HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Procedure, Drug, Radiation, Other

Study Drugs: Carboplatin, Hyaluronidase-zzxf+Pertuzumab+Trastuzumab, Paclitaxel, Trastuzumab+Hyaluronidase-oysk

Study Phase: Phase 3

Summary: This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to spe...

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.

View All Clinical Trials